Aurora, COLORADO2 Active Studies

Triple Negative Breast Cancer Clinical Trials in Aurora, COLORADO

Find 2 actively recruiting triple negative breast cancer clinical trials in Aurora, COLORADO. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
1,185
Enrolling

Recruiting Triple Negative Breast Cancer Studies in Aurora

About Triple Negative Breast Cancer Clinical Trials in Aurora

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.

There are currently 2 triple negative breast cancer clinical trials recruiting participants in Aurora, COLORADO. These studies are seeking a combined 1,185 participants. Research is being sponsored by AstraZeneca, Bristol-Myers Squibb. Clinical trial participation is free and participants receive study-related medical care at no cost.

Triple Negative Breast Cancer Clinical Trials in Aurora — FAQ

Are there triple negative breast cancer clinical trials in Aurora?

Yes, there are 2 triple negative breast cancer clinical trials currently recruiting in Aurora, COLORADO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What triple negative breast cancer treatments are being tested?

The 2 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for triple negative breast cancer.

Data updated March 2, 2026 from ClinicalTrials.gov